Inactive Instrument

Highlights Aerie Pharmaceuticals, Inc.

Equities

AERI

US00771V1089

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alcon Completes Acquisition of Aerie Pharmaceuticals for $930 Million	22-11-22	MT
Alcon Concludes $930 Million Purchase of US-based Aerie Pharmaceuticals	22-11-22	MT
Alcon Research, Ltd. completed the acquisition of Aerie Pharmaceuticals, Inc. from a group of shareholders.	22-11-20	CI
Aerie Pharmaceuticals : Merger Agreement - Form 8-K	22-11-07	PU
Aerie Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Earnings Flash (AERI) AERIE PHARMACEUTICALS Reports Q3 Loss $-0.27	22-11-03	MT
Earnings Flash (AERI) AERIE PHARMACEUTICALS Posts Q3 Revenue $36.1M	22-11-03	MT
Alcon to Acquire Aerie Pharmaceuticals in $770 Million Deal	22-08-23	MT
Alcon to Acquire Aerie Pharmaceuticals in $770 Million Deal; Shares Rise Tuesday	22-08-23	MT
Aerie Pharmaceuticals Shares Rise 34% After Alcon Buyout Offer	22-08-23	DJ
Alcon to Expand Eye Treatment Portfolio with $770 Million Purchase of Aerie	22-08-22	MT
Swiss eye-care firm Alcon to buy Aerie Pharma for about $753 mln	22-08-22	RE
Alcon Research, Ltd. entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. from a group of shareholders for approximately $750 million.	22-08-21	CI
Aerie Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI
Aerie Pharmaceuticals, Inc. Reiterates Revenue Guidance for the Year 2022	22-08-04	CI
Earnings Flash (AERI) AERIE PHARMACEUTICALS Posts Q2 Revenue $33.3M	22-08-04	MT
Earnings Flash (AERI) AERIE PHARMACEUTICALS Reports Q2 Loss $-0.32	22-08-04	MT
Aerie Pharmaceuticals, Inc. Announces First Participant Dosed in the Comet-3 Study of Ar-15512 for the Treatment of Dry Eye Disease	22-08-01	CI
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease	22-05-24	CI
Aerie Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aerie Pharmaceuticals, Inc.

Equities

AERI

US00771V1089

Highlights

Filters